<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621217</url>
  </required_header>
  <id_info>
    <org_study_id>NOAC8.Version1</org_study_id>
    <nct_id>NCT01621217</nct_id>
  </id_info>
  <brief_title>Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (&gt;4 cm) - T4 N0-3 M0 or Any T N2-3 M0</brief_title>
  <acronym>NOAC8</acronym>
  <official_title>Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (&gt;4 cm) - T4 N0-3 M0 or Any T N2-3 M0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and
           mitomycin C when given together with the antibody cetuximab in patients with locally
           advanced cancer in the anal region

        -  To evaluate acute toxicity

        -  To evaluate late toxicity

        -  To evaluate response rate

        -  To evaluate recurrence free survival

        -  To evaluate overall survival
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region</measure>
    <time_frame>Participating patients will be followed during the study period; 8 weeks.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Locally Advanced Cancer in the Anal Region</condition>
  <arm_group>
    <arm_group_label>Cetuximab, Mitomycin C, Fluoruracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Will be given weekly intravenously during study treatment.</description>
    <arm_group_label>Cetuximab, Mitomycin C, Fluoruracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Will be given intravenously twice together with 5-Fluoruracil during study treatment.</description>
    <arm_group_label>Cetuximab, Mitomycin C, Fluoruracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluoruracil</intervention_name>
    <description>Will be given intravenously twice together with Mitomycin C during study treatment</description>
    <arm_group_label>Cetuximab, Mitomycin C, Fluoruracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.</description>
    <arm_group_label>Cetuximab, Mitomycin C, Fluoruracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Histologically or cytologically confirmed squamous cell cancer of the anal region
             (anal canal or anal margin or distal rectum)

          -  Stage T2 (≥4 cm) - T4 N0-3 M0 or any T N2-3 M0

          -  ECOG performance status 0-1

          -  Hb &gt; 100 g/L

          -  ANC &gt; 1.5 x 10 9/L

          -  Platelets ≥ 100 x 10 9/L

          -  Creatinine &lt; 1.5 x ULN

          -  Bilirubin &lt; 1.5 x ULN

          -  ALAT &lt; 3.0 x ULN

          -  Competent to comprehend, sign and date an approved informed consent form

        Exclusion Criteria:

          -  Previous pelvic irradiation

          -  Previous chemotherapy for anal cancer

          -  Previous malignancy within the last 5 years, except curatively treated non-melanoma
             skin cancer or carcinoma in situ of the cervix uteri

          -  Pregnant or nursing females or patients of child-bearing potential not using adequate
             methods of birth control

          -  Patients with active infections or any other serious underlying medical condition,
             which would impair the ability of the patients to receive the protocol treatment

          -  Known hypersensitivity to any of the components of the treatment

          -  Clinically significant cardiovascular disease, e.g. cardiac failure (&lt;12 months before
             treatment start), unstable angina, congestive heart failure, arrythmia requiring
             medication, or uncontrolled hypertension

          -  Known positive test for hepatitis C virus, chronic active hepatitis B infection

          -  Known HIV infection

          -  Any other condition or therapy which in the investigator´s opinion may pose a risk to
             the patient or interfere with the study objectives

          -  Any investigational agent within 30 days before enrolment

          -  Surgery (excluding diagnostic biopsy or central venous catheter placement) and/or
             radiotherapy within 28 days prior to inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Johnsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skåne University Hospital, Dept. of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Dept. of Oncology</name>
      <address>
        <city>Oslo</city>
        <zip>4950</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, Dept. of Oncology</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accademic Hospital, Dept. of Oncology</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anal cancer</keyword>
  <keyword>Locally advanced anal cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>5-fluoruracil</keyword>
  <keyword>Mitomycin C</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

